In 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates, the Selective 5-Hydroxytryptamine 1a Agonist (R)-(+)-8-OHDPAT Inhibits Levodopa-Induced Dyskinesia but Only with\ Increased Motor Disability
Open Access
- 7 September 2006
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 319 (3), 1225-1234
- https://doi.org/10.1124/jpet.106.110429
Abstract
5-Hydroxytryptamine 1a (5-HT1a) receptor agonists, such as sarizotan and tandospirone, are reported to reduce levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques and in Parkinson's disease without worsening motor disability. However, these compounds are not specific for 5-HT1a receptors and also possess dopamine antagonist actions. We now report on the effects of (2R)-(+)-8-hydroxy-2-(di-n-propylamino)tetralin [(R)-(+)-8-OHDPAT], a selective 5-HT1a agonist lacking dopaminergic activity, on motor disability and dyskinesia (chorea and dystonia) in levodopa-primed MPTP-treated common marmosets. Administration of (R)-(+)-8-OHDPAT (0.2, 0.6, and 2.0 mg/kg s.c), in conjunction with levodopa/carbidopa (12.5 mg/kg each p.o.) to levodopa-primed animals, dose-dependently reduced levodopa-induced chorea but did not affect dystonic movements. However, (R)-(+)-8-OHDPAT treatment also reduced locomotor activity and the reversal of motor disability. Administration of (R)-(+)-8-OHDPAT alone had no effects of motor behaviors. The effects of (R)-(+)-8-OHDPAT on levodopa-induced motor behaviors were antagonized by the 5-HT1a receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate (WAY-100635) (1.0 mg/kg s.c.). Administration of (R)-(+)-8-OHDPAT (0.6 mg/kg s.c.) also reduced chorea produced by the administration of the D2/D3 dopamine receptor agonist pramipexole (0.06 mg/kg p.o.) to levodopa-primed MPTP-treated animals. However, again the increase in locomotor activity and reversal of motor disability produced by pramipexole were also inhibited. These data suggest that selective 5-HT1a agonists do not provide an effective means of suppressing levodopa-induced dyskinesia, except with worsening of parkinsonism.Keywords
This publication has 43 references indexed in Scilit:
- Amantadine reduces the duration of levodopa-induced dyskinesia: A randomized, double-blind, placebo-controlled studyParkinsonism & Related Disorders, 2005
- Effects of sarizotan on the corticostriatal glutamate pathwaysSynapse, 2005
- Effects of serotonin 5‐HT1A agonist in advanced Parkinson's diseaseMovement Disorders, 2005
- Sarizotan, a serotonin 5-HT 1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profileJournal of Neural Transmission, 2004
- Amantadine for dyskinesia in Parkinson's diseaseCochrane Database of Systematic Reviews, 2003
- Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathiesAnnals of Neurology, 2000
- Buspirone in Levodopa-Induced DyskinesiasClinical Neuropharmacology, 1994
- Increased dopamine turnover in the ventral striatum by 8-OH-DPAT administration in the ratJournal of Pharmacy and Pharmacology, 1990
- Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brainJournal of Medicinal Chemistry, 1989
- Inhibition of SKF 38393- and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-1 and D-2 receptor affinitiesin vitroJournal of Neural Transmission, 1986